Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$104.77 USD
-0.47 (-0.45%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $104.41 -0.36 (-0.34%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Brokerage Reports
Abbott Laboratories [ABT]
Reports for Purchase
Showing records 501 - 520 ( 534 total )
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Med Tech September Quarter Preview: Stagnation for Most Large Device Markets
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
A Very Busy Week -Beetles and Bardoxolone, Integrating Solvay, SPIRIT IV at Two Years and More to ABSORB
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Likely approval of Bioresorbable stent to further strengthen long term growth prospects.
Provider: FIRST GLOBAL
Analyst: THOMAS K
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
FDA Panel Meets Wednesday to Decide Fate of Obesity Drug Meridia - Potential for More Negative Headlines, But No Material Damage to ABT Even if Drug Pulled From Market
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
This House Is Still Standing Stronger than Ever as Most of the Neighborhood Falls Down Around it - the Big Cap Health Care Product Name to Buy Now
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Medical Technology -Med Tech June Quarter Preview: Nothing on the Horizon to Lift the Sector Out of the Doldrums, Although Select Small-Cap Names Should Shine Through
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
EuroPCR Events Suggest ABT Likely to Retain Dominance in DES for Years to Come Share Gains in Balloons Likely to Accelerate, to the Detriment of BSX -- Big Mitral Valve Opportunity Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
A Very Big Step In The Push To Build A Major Branded Generics/Emerging Markets Franchise - 2010 EPS View Intact - Own ABT When The Dust Settles
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Tour Guide to ASCO 2010-Our Take on the (Many) Abstracts of Interest.
Provider: WEDBUSH SECURITIES INC.
Analyst: BANK P
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Company: Abbott Laboratories
Industry: Large Cap Pharmaceuticals
Solid Q1 Results - Full-Year View Trimmed Due to Reform Tab - We View Stock as High-Quality Value Opportunity
Provider: WEDBUSH SECURITIES INC.
Analyst: NALBONE P